Goldman Sachs
MBX icon

Goldman Sachs’s MBX Biosciences MBX Stock Holding History

Goldman Sachs’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
459,005
+1,060
+0.2% +$37K ﹤0.01% 2412
2026
Q1 		$13.7M Buy
457,945
+126,007
+38% +$4.29M ﹤0.01% 2791
2025
Q4 		$10.5M Sell
331,938
-26,183
-7% -$635K ﹤0.01% 3056
2025
Q3 		$6.27M Buy
+358,121
New +$4.79M ﹤0.01% 3445
2025
Q2 		– Sell
-15,168
Closed -$112K – 6525
2025
Q1 		$112K Sell
15,168
-19,659
-56% -$208K ﹤0.01% 5766
2024
Q4 		$642K Sell
34,827
-16,173
-32% -$345K ﹤0.01% 5100
2024
Q3 		$1.32M Buy
+51,000
New +$1.17M ﹤0.01% 4444

Other funds holding MBX

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NVP Associates
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Goldman Sachs's MBX Position: Q2 2026 in Review

Goldman Sachs increased its MBX Biosciences (MBX) stake by 0.23% in Q2 2026, buying an estimated $37K and bringing the position to 459,005 shares worth $25.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

Goldman Sachs first reported a position in MBX in Q3 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Goldman Sachs held 459,005 shares of MBX Biosciences worth $25.3M as of Q2 2026.
  • Goldman Sachs bought 1,060 MBX Biosciences shares in Q2 2026, an estimated $37K.
  • MBX Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2412 holding.
  • Goldman Sachs first reported a position in MBX Biosciences in Q3 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.